Pyrrolotriazine kinase inhibitors

A compound of the formula I

• wherein:
• R1 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl or —CONR4R5;
• R2 is hydrogen or C1-C4 alkyl;
• R3 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl,
• heteroaryl, substituted heteroaryl, heterocyclyl, substituted heterocyclyl, —CONHR4, —CONHSO2R4, —(CH2)n-aryl, —(CH2)n-substituted aryl, —(CH2)n-heteroaryl, —(CH2)n-substituted heteroaryl, —(CHR4)nCONHalkyl, —(CHR4)nCONHsubstituted aryl, —(CHR4)nCONH heteroaryl, —(CHR4)nCONHsubstituted heteroaryl, —(CHR4)nCONH(CH2)n, —OH, —(CH2)2(CH2)n—OH, —(CH2)2(CH2)n—NH2 or —(CH2)2(CH2)n—S-alkyl, two of which may be attached to the same ring carbon atom;
• R4 and R5 are independently hydrogen, C1-C4 alkyl or phenyl;
• R6 and R7 are independently hydrogen, C1-C4 alkyl, halogen, cyano, amino or substituted amino;
• R8 is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C3-C8 cycloalkyl, C1-C5 arylalkyl or C4-C8 heterocyclyl with at least one atom on the ring selected from a nitrogen or oxygen atom, and each of said R8 groups optionally substituted with 1 to 3 groups selected from the group consisting of —OH, OR9, —NH2, —NR9R10, —CONHR9, —OCONHR9, —CONHSO2R9, —NHCONHR9, —SR9, —S(═O)R9, —SO2R9 and —SO2NR9R10;
• R9 is C1-C6 alkyl, C3-C6 cycloalkyl, an optionally substituted aryl or heteroaryl group;
• said substituents on the substituted aryl or substituted heteroaryl group are one or more hydrogen, halogen, alkyl, substituted alkyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxy or substituted aryloxy;
• R10 is hydrogen, halogen, C1-C6 alkyl, C1-C6 cycloalkyl or C1-C6 alkoxy;
• n is 0, 1, 2, 3 or 4;
• or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.